Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00034944
Recruitment Status : Completed
First Posted : May 3, 2002
Last Update Posted : May 5, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: MK0869, aprepitant Drug: Comparator: placebo Phase 3

Detailed Description:
The duration of treatment is 8 weeks.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 495 participants
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder
Actual Study Start Date : January 24, 2002
Actual Primary Completion Date : December 17, 2003
Actual Study Completion Date : December 17, 2003

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. HAMD-17 total score at week 8. Tolerability.

Secondary Outcome Measures :
  1. CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Major depressive disorder

Study Data/Documents: CSR Synopsis  This link exits the site

Publications of Results:
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00034944     History of Changes
Other Study ID Numbers: 0869-063
First Posted: May 3, 2002    Key Record Dates
Last Update Posted: May 5, 2017
Last Verified: May 2017

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Neurokinin-1 Receptor Antagonists
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action